News und Analysen
EQS-News: Half-year results: Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive
EQS-News: Half-year results: Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive
EQS-Adhoc: Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024
EQS-Adhoc: Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024
EQS-News: MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
EQS-News: MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
EQS-Adhoc: Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
EQS-Adhoc: Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
EQS-News: Gerresheimer remains on track in 1st half year 2024
EQS-News: Gerresheimer remains on track in 1st half year 2024
Why Lantheus Holdings Stock Is Skyrocketing Today
Shares of Lantheus Holdings (NASDAQ: LNTH) were skyrocketing on Wednesday, up 34% as of 11:20 a.m. ET. The big gain came after the Centers for Medicare and Medicaid Services (CMS) released a
EQS-News: Evotec and Pfizer collaborate to advance drug discovery in France
EQS-News: Evotec and Pfizer collaborate to advance drug discovery in France
EQS-News: Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
EQS-News: Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, launched its new sustainability strategy Act4Impact 2030 today. The updated strategy aims at transforming
EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret
EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret
EQS-Adhoc: SARTORIUS AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office
EQS-Adhoc: SARTORIUS AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office
EQS-News: Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
EQS-News: Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
EQS-Adhoc: Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
EQS-Adhoc: Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
Lockheed Martin Gives Thumbs Up to 1 Tiny Space Stock
Valued at $110 billion and doing nearly $70 billion in annual business, Lockheed Martin (NYSE: LMT) is the world's biggest defense company. It's also a major player in space.
Lockheed Martin builds
EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
EQS-News: Evotec SE: Results of the Annual General Meeting 2024
EQS-News: Evotec SE: Results of the Annual General Meeting 2024
EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases
EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases
EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
EQS-News: Gerresheimer expands capacities for Medical Systems in the USA
EQS-News: Gerresheimer expands capacities for Medical Systems in the USA
EQS-News: Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Strategic reset of Moulded Glass business
EQS-News: Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Strategic reset of Moulded Glass business
EQS-Adhoc: Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group / Moulded Glass business to be strategically reviewed
EQS-Adhoc: Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group / Moulded Glass business to be strategically reviewed
EQS-News: Evotec reports Q1 2024 results and provides corporate update
EQS-News: Evotec reports Q1 2024 results and provides corporate update
EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA